301. Macular dystrophy Disease details / Clinical trials / Drug dev / DR info

Clinical trials : 46 /  Drugs : 42 - (DrugBank : 11) / Drug target genes : 9 - Drug target pathways : 67

Drugs and their primary sponsors and trial info
(7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine   
   Katairo GmbH
      2019   Phase 2   EUCTR2018-001496-20-IT   Germany;Italy;Netherlands;United Kingdom;
ACU-4429   
   Acucela Inc.
      2019   Phase 3   EUCTR2018-003498-82-IT   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
ALK-001   
   Alkeus Pharmaceuticals, Inc.
      2019   Phase 2   NCT04239625   United States;
      2015   Phase 2   NCT02402660   United States;
ALK-001 (No generic name)   
   Alkeus Pharmaceuticals, Inc.
      2014   Phase 1   NCT02230228   -
ARC1905   
   IVERIC bio, Inc.
      2018   Phase 2   EUCTR2017-004783-35-IT   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
ARC1905 20 MG/ML   
   IVERIC bio
      2018   Phase 2   EUCTR2017-004783-35-HU   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004783-35-GB   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004783-35-DE   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
   OPHTHOTECH CORPORATION
      2018   Phase 2   EUCTR2017-004783-35-ES   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
Avacincaptad pegol   
   IVERIC bio
      2018   Phase 2   EUCTR2017-004783-35-HU   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004783-35-GB   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004783-35-DE   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
   IVERIC bio, Inc.
      2018   Phase 2   EUCTR2017-004783-35-IT   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
   OPHTHOTECH CORPORATION
      2018   Phase 2   EUCTR2017-004783-35-ES   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
Docosahexaenoic Acid (DHA) Dietary Supplement   
   National Eye Institute (NEI)
      2003   Phase 1   NCT00060749   United States;
EMIXUSTAT HYDROCHLORIDE (ACU-4429)   
   Acucela Inc.
      2019   Phase 3   EUCTR2018-003498-82-NL   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003498-82-GB   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003498-82-ES   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003498-82-DK   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-003498-82-FR   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-003498-82-DE   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
EU/3/13/1208 orphan   
   Katairo GmbH
      2019   Phase 2   EUCTR2018-001496-20-IT   Germany;Italy;Netherlands;United Kingdom;
Emixustat   
   Kubota Vision Inc.
      2018   Phase 3   NCT03772665   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
      2017   Phase 2   NCT03033108   United States;
Emixustat hydrochloride   
   Acucela Inc.
      2019   Phase 3   EUCTR2018-003498-82-IT   Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
HESC-RPE   
   Astellas Institute for Regenerative Medicine
      2013   -   NCT02941991   United Kingdom;
Interferon gamma-1b   
   National Eye Institute (NEI)
      2015   Phase 1/Phase 2   NCT02338973   United States;
Lentiviral vector containing ABCA4 gene   
   Oxford BioMedica (UK) Ltd
      2011   Phase 1;Phase 2   EUCTR2010-023111-34-FR   France;Italy;Netherlands;
   sanofi-aventis recherche et développement
      2016   -   EUCTR2010-023111-34-NL   France;Italy;Netherlands;United States;
Long term follow up in all patients who received SAR422459 in previous study TDU13583   
   Sanofi
      2012   Phase 1/Phase 2   NCT01736592   France;United States;
MA09-hRPE   
   Astellas Institute for Regenerative Medicine
      2012   -   NCT02445612   United States;
      2011   Phase 1/Phase 2   NCT01469832   United Kingdom;
      2011   Phase 1/Phase 2   NCT01345006   United States;
   CHABiotech CO., Ltd
      2012   Phase 1   NCT01625559   Korea, Republic of;
Madeos   
   Ophthalmos Research and Education Institute
      2019   -   NCT03297515   France;Germany;Italy;
Metformin hydrochloride   
   National Eye Institute (NEI)
      2020   Phase 1/Phase 2   NCT04545736   United States;
Over the counter DHA/EPA dietary supplementation   
   University of Utah
      2007   -   NCT00420602   United States;
Ranibizumab injection (0.5 mg)   
   Manhattan Eye, Ear & Throat Hospital
      2007   Phase 1/Phase 2   NCT00470977   United States;
SAR422459   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2018   Phase 1;Phase 2   EUCTR2010-023111-34-IT   France;Italy;Netherlands;United States;
   Sanofi
      2011   Phase 1/Phase 2   NCT01367444   France;United States;
   sanofi-aventis recherche et développement
      2016   -   EUCTR2010-023111-34-NL   France;Italy;Netherlands;United States;
STG-001   
   Stargazer Pharmaceuticals, Inc.
      2020   Phase 2   NCT04489511   United States;
Saffron supplementation   
   Catholic University of the Sacred Heart
      2011   Phase 1/Phase 2   NCT01278277   Italy;
Sildenafil   
   Columbia University
      2014   Phase 2   NCT04356716   United States;
Soraprazan   
   Katairo GmbH
      2019   Phase 2   EUCTR2018-001496-20-IT   Germany;Italy;Netherlands;United Kingdom;
StarGen   
   Oxford BioMedica (UK) Ltd
      2011   Phase 1;Phase 2   EUCTR2010-023111-34-FR   France;Italy;Netherlands;
Stem/progenitor cells transplantation   
   Pomeranian Medical University Szczecin
      2018   Phase 1   NCT03772938   Poland;
Tinlarebant   
   Belite Bio, Inc
      2022   Phase 3   NCT05244304   Australia;France;Germany;Hong Kong;Switzerland;Taiwan;United Kingdom;United States;
   RBP4 Pty Ltd
      2021   Phase 1/Phase 2   NCT05266014   Australia;Taiwan;
VA   
   Columbia University
      2014   Phase 2   NCT04356716   United States;
Vett Lentiviral con gene ABCA4   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2018   Phase 1;Phase 2   EUCTR2010-023111-34-IT   France;Italy;Netherlands;United States;
Zimura   
   IVERIC bio
      2018   Phase 2   EUCTR2017-004783-35-HU   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004783-35-GB   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004783-35-DE   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
   IVERIC bio, Inc.
      2018   Phase 2   NCT03364153   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004783-35-IT   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
   OPHTHOTECH CORPORATION
      2018   Phase 2   EUCTR2017-004783-35-ES   Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;